MX383471B - Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. - Google Patents
Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.Info
- Publication number
- MX383471B MX383471B MX2016006625A MX2016006625A MX383471B MX 383471 B MX383471 B MX 383471B MX 2016006625 A MX2016006625 A MX 2016006625A MX 2016006625 A MX2016006625 A MX 2016006625A MX 383471 B MX383471 B MX 383471B
- Authority
- MX
- Mexico
- Prior art keywords
- cell receptor
- modified
- cell receptors
- genetic manipulation
- affinity human
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 5
- 238000010353 genetic engineering Methods 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract 1
- 108010002687 Survivin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un receptor de células T modificado, o un fragmento de unión al antígeno del mismo, que comprende una Va y una Vß derivadas de un receptor de células T de tipo salvaje, en donde la Va o la Vß o ambas comprende una mutación en una o más regiones determinantes de complementariedad (CDR) en relación con el receptor de células T de tipo salvaje, en donde la Va comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEQ ID NO: 1 y SEQ ID NO: 2, y en donde el receptor de células T modificado se une a un complejo del péptido Survivina y la molécula HLA-A2 con un valor KD de 10-6 M a 10-12 M.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907887P | 2013-11-22 | 2013-11-22 | |
| PCT/US2014/066892 WO2015077607A1 (en) | 2013-11-22 | 2014-11-21 | Engineered high-affinity human t cell receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006625A MX2016006625A (es) | 2016-12-02 |
| MX383471B true MX383471B (es) | 2025-03-14 |
Family
ID=53180203
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006625A MX383471B (es) | 2013-11-22 | 2014-11-21 | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. |
| MX2016006620A MX371202B (es) | 2013-11-22 | 2014-11-21 | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. |
| MX2021006932A MX2021006932A (es) | 2013-11-22 | 2016-05-20 | Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006620A MX371202B (es) | 2013-11-22 | 2014-11-21 | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. |
| MX2021006932A MX2021006932A (es) | 2013-11-22 | 2016-05-20 | Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica. |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10023625B2 (es) |
| EP (2) | EP3071594A4 (es) |
| JP (4) | JP6476182B2 (es) |
| KR (2) | KR102415259B1 (es) |
| CN (2) | CN105873945B (es) |
| AU (4) | AU2014352826B2 (es) |
| BR (1) | BR112016011567A2 (es) |
| CA (2) | CA2930847A1 (es) |
| DK (1) | DK3071593T3 (es) |
| ES (1) | ES2729406T3 (es) |
| IL (2) | IL245468B (es) |
| MX (3) | MX383471B (es) |
| PL (1) | PL3071593T3 (es) |
| PT (1) | PT3071593T (es) |
| RU (2) | RU2729383C2 (es) |
| SA (1) | SA516371174B1 (es) |
| SG (2) | SG10201804335QA (es) |
| TR (1) | TR201908404T4 (es) |
| WO (2) | WO2015077607A1 (es) |
| ZA (2) | ZA201603116B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| EP2010209B1 (en) | 2006-04-10 | 2016-06-15 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| PL2945647T3 (pl) | 2013-01-15 | 2021-03-08 | Memorial Sloan Kettering Cancer Center | Immunogenne peptydy wt-1 i sposoby ich zastosowania |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| EP3071594A4 (en) | 2013-11-22 | 2017-05-03 | The Board of Trustees of the University of Illionis | Engineered high-affinity human t cell receptors |
| CN108601849A (zh) * | 2015-09-22 | 2018-09-28 | 尤利乌斯·马克西米利安维尔茨堡大学 | 一种在淋巴细胞中高水平的和稳定的基因转移的方法 |
| US12364757B2 (en) | 2015-10-01 | 2025-07-22 | Ospedale San Raffaele S.R.L | TCR and uses thereof |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| EP3394092A1 (en) * | 2015-12-23 | 2018-10-31 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| CA3042890A1 (en) | 2016-11-14 | 2018-05-17 | Fred Hutchinson Cancer Research Center | High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
| MX2019010972A (es) * | 2017-03-15 | 2019-12-02 | Hutchinson Fred Cancer Res | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. |
| CN110785432B (zh) * | 2017-04-24 | 2024-12-27 | 圣拉斐尔医院有限责任公司 | Tcr和肽 |
| JP7181517B2 (ja) | 2018-01-23 | 2022-12-01 | 国立大学法人三重大学 | Ｔ細胞レセプター |
| CN112739339B (zh) * | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| WO2020185796A1 (en) | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| CN114555790B (zh) * | 2019-08-20 | 2025-02-25 | 弗雷德哈钦森癌症中心 | Wt-1特异性t细胞免疫疗法 |
| CN115335404A (zh) * | 2020-02-12 | 2022-11-11 | 艾伯维公司 | 双特异性结合分子 |
| KR20230002554A (ko) | 2020-04-28 | 2023-01-05 | 아킬레스 테라퓨틱스 유케이 리미티드 | T 세포 요법 |
| CN112239495B (zh) * | 2020-10-29 | 2022-04-12 | 上海药明生物技术有限公司 | 稳定的tcr结构及应用 |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| WO2022214835A1 (en) | 2021-04-09 | 2022-10-13 | Achilles Therapeutics Uk Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| JP2024524185A (ja) | 2021-06-22 | 2024-07-05 | アキレス セラピューティクス ユーケー リミテッド | 抗原特異的ｔ細胞を生成するための方法 |
| KR20240046834A (ko) * | 2021-07-19 | 2024-04-09 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Fanci, rad51, 및 pbk 항원을 표적화하는 펩타이드 및 가공된 t 세포 수용체 및 이의 사용 방법 |
| CN119220425A (zh) * | 2023-07-28 | 2024-12-31 | 佳吾益(北京)科技有限公司 | 发现mhc新抗原肽表位的工程化细胞 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4640561A (en) | 1985-11-15 | 1987-02-03 | Ford Motor Company | Flexible printed circuit connector |
| US5059413A (en) | 1988-04-18 | 1991-10-22 | Xoma Corporation | Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators |
| ATE172879T1 (de) | 1989-08-09 | 1998-11-15 | Rhomed Inc | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium |
| US5299253A (en) | 1992-04-10 | 1994-03-29 | Akzo N.V. | Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| ATE370967T1 (de) | 1998-10-21 | 2007-09-15 | Altor Bioscience Corp | Polyspezifische bindemoleküle und deren verwendung |
| ATE290020T1 (de) * | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| WO2005113595A2 (en) | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
| ATE408684T1 (de) | 2004-05-19 | 2008-10-15 | Medigene Ltd | Verfahren zur verbesserung von t-zellrezeptoren |
| GB0524477D0 (en) | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| EP2352756B1 (en) * | 2008-11-24 | 2012-09-19 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | High affinity t cell receptor and use thereof |
| WO2010075417A1 (en) * | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Survivin specific t cell receptor for treating cancer |
| US9409969B2 (en) | 2009-02-09 | 2016-08-09 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| EP2598528A1 (en) * | 2010-07-28 | 2013-06-05 | Immunocore Ltd. | T cell receptors |
| BR112013006718B1 (pt) | 2010-09-20 | 2021-12-07 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
| RU2018130123A (ru) * | 2012-05-03 | 2018-11-07 | Фред Хатчинсон Кансэр Рисёч Сентер | Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии |
| WO2014191465A1 (en) * | 2013-05-28 | 2014-12-04 | Møller Niels Iversen | Peptides derived from lawsonia intracellularis and their use in vaccination |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| EP3071594A4 (en) | 2013-11-22 | 2017-05-03 | The Board of Trustees of the University of Illionis | Engineered high-affinity human t cell receptors |
| WO2016022400A1 (en) | 2014-08-04 | 2016-02-11 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| CN113105562B (zh) * | 2018-09-26 | 2023-12-01 | 安源医药科技（上海）有限公司 | 突变型单链人凝血因子viii在制备融合蛋白中的应用 |
-
2014
- 2014-11-21 EP EP14864079.0A patent/EP3071594A4/en active Pending
- 2014-11-21 BR BR112016011567A patent/BR112016011567A2/pt not_active Application Discontinuation
- 2014-11-21 RU RU2016124163A patent/RU2729383C2/ru active
- 2014-11-21 US US15/037,476 patent/US10023625B2/en active Active
- 2014-11-21 AU AU2014352826A patent/AU2014352826B2/en active Active
- 2014-11-21 AU AU2014352834A patent/AU2014352834B2/en not_active Ceased
- 2014-11-21 JP JP2016533150A patent/JP6476182B2/ja active Active
- 2014-11-21 RU RU2016124179A patent/RU2740648C2/ru active
- 2014-11-21 KR KR1020167016131A patent/KR102415259B1/ko active Active
- 2014-11-21 WO PCT/US2014/066892 patent/WO2015077607A1/en not_active Ceased
- 2014-11-21 PT PT14863490T patent/PT3071593T/pt unknown
- 2014-11-21 CA CA2930847A patent/CA2930847A1/en not_active Abandoned
- 2014-11-21 PL PL14863490T patent/PL3071593T3/pl unknown
- 2014-11-21 CA CA2930852A patent/CA2930852C/en active Active
- 2014-11-21 MX MX2016006625A patent/MX383471B/es unknown
- 2014-11-21 MX MX2016006620A patent/MX371202B/es active IP Right Grant
- 2014-11-21 DK DK14863490.0T patent/DK3071593T3/da active
- 2014-11-21 SG SG10201804335QA patent/SG10201804335QA/en unknown
- 2014-11-21 US US15/037,485 patent/US10344075B2/en active Active
- 2014-11-21 WO PCT/US2014/066903 patent/WO2015077615A1/en not_active Ceased
- 2014-11-21 JP JP2016533163A patent/JP6697386B2/ja not_active Expired - Fee Related
- 2014-11-21 ES ES14863490T patent/ES2729406T3/es active Active
- 2014-11-21 TR TR2019/08404T patent/TR201908404T4/tr unknown
- 2014-11-21 KR KR1020167016132A patent/KR20160085345A/ko not_active Ceased
- 2014-11-21 EP EP14863490.0A patent/EP3071593B1/en active Active
- 2014-11-21 CN CN201480071620.2A patent/CN105873945B/zh active Active
- 2014-11-21 CN CN201480071635.9A patent/CN105899530B/zh not_active Expired - Fee Related
- 2014-11-21 SG SG10201804330YA patent/SG10201804330YA/en unknown
-
2016
- 2016-05-04 IL IL245468A patent/IL245468B/en active IP Right Grant
- 2016-05-04 IL IL245467A patent/IL245467B/en not_active IP Right Cessation
- 2016-05-10 ZA ZA2016/03116A patent/ZA201603116B/en unknown
- 2016-05-11 ZA ZA2016/03169A patent/ZA201603169B/en unknown
- 2016-05-20 MX MX2021006932A patent/MX2021006932A/es unknown
- 2016-05-21 SA SA516371174A patent/SA516371174B1/ar unknown
-
2018
- 2018-05-25 US US15/990,524 patent/US20190055298A1/en not_active Abandoned
-
2019
- 2019-10-17 JP JP2019190139A patent/JP6970724B2/ja not_active Expired - Fee Related
- 2019-11-28 AU AU2019272003A patent/AU2019272003B2/en not_active Ceased
-
2021
- 2021-04-15 AU AU2021202274A patent/AU2021202274A1/en not_active Abandoned
- 2021-11-01 JP JP2021178468A patent/JP2022023196A/ja active Pending
-
2022
- 2022-01-27 US US17/586,652 patent/US20220396606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383471B (es) | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. | |
| CY1124515T1 (el) | Συνθεσεις αντι-cgrp και χρησεις αυτων | |
| CY1125008T1 (el) | Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων | |
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| MX2020006408A (es) | Moléculas de unión al antígeno biespecíficas. | |
| ECSP14013307A (es) | Genzyme corporation | |
| CY1118994T1 (el) | Πρωτεϊνες συνδεσης αντιγονου il-17 υποδοχεα α | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
| AR108066A1 (es) | Receptores quiméricos para cll-1 y métodos de uso de los mismos | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| NZ711451A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| AR077594A1 (es) | Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t) | |
| PH12017502190A1 (en) | T-cell receptor specific antibodies | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| MX2014008468A (es) | Complementacion funcional bipartita inducida por antigenos, dual. | |
| MX2017000083A (es) | Compuestos de platino, composiciones y usos de estos. | |
| EA201792485A3 (ru) | Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты) | |
| NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
| CR20120127A (es) | Anticuerpos monoclonales | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| UA117097C2 (uk) | Антитіло проти лігандів рецептора в1 брадикініну | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof |